ArticleOncoTargets and therapy2021
HSDL2 Acts as a Promoter in Pancreatic Cancer by Regulating Cell Proliferation and Lipid Metabolism.
Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- DIP2B as a Prognostic Biomarker and Immunotherapy Target: Insights from Pan-Cancer Analysis.Applied biochemistry and biotechnology · 2026Article
- Systems approach identifies monocyte imbalance in symptomatic and asymptomatic P. vivax malaria.Molecular systems biology · 2025Article
- Identification and validation of cholesterol metabolism-related gene GNB3 as prognosis biomarker for pancreatic adenocarcinoma.Discover oncology · 2025Article
- Targeting lipid metabolism: novel insights and therapeutic advances in pancreatic cancer treatment.Lipids in health and disease · 2025Review
- HSDL2 links nutritional cues to bile acid and cholesterol homeostasis.Science advances · 2024Article
- Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2.Drug design, development and therapy · 2024Article
- HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.World journal of surgical oncology · 2023Article
- [HSDL2 overexpression promotes rectal cancer progression by regulating cancer cell cycle and promoting cell proliferation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Bioinformatic analysis of short-chain dehydrogenase/reductase proteins in plant peroxisomes.Frontiers in plant science · 2023Article
- Effects of High-Fat Diet on Cardiovascular Protein Expression in Mice Based on Proteomics.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- MiR-26a-5p regulates proliferation, apoptosis, migration and invasion via inhibiting hydroxysteroid dehydrogenase like-2 in cervical cancer cell.BMC cancer · 2022Article
- Cucurbitacin E inhibits cellular proliferation and induces apoptosis in melanoma by suppressing HSDL2 expression.Chinese medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) is a leading cause of cancer mortality worldwide. Hydroxysteroid dehydrogenase like protein 2 (HSDL2) is overexpressed in a variety of malignant tumors and is might be closely related to the development of cancer. It also regulates different metabolism and signaling pathways. PURPOSE: The purpose of this research was to find HSDL2 expression levels and investigate its underlying molecular mechanism in PC. PATIENTS AND
methodsIn the present study, a total of 66 PC samples and 54 normal tissues were used to examine the expression of HSDL2. In order to gain a broader insight into the molecular mechanism of HSDL2 in PC, the HSDL2 siRNA sequences were transfected into PC cell lines (Bxpc-3 and Panc-1), respectively. Cell proliferation was measured by MTT, colony formation assay and EdU assays. Furthermore, the lipid metabolism process was evaluated by triglyceride and phospholipid assay kits, BODIPY 493/503 staining and the expression of several pivotal lipid metabolic enzymes in PC.
resultsIn this study, HSDL2 was highly expressed in PC and connected with shorter overall survival. When HSDL2 was silenced, the cell proliferation was significantly reduced, and the lipid metabolism was further inhibited.
conclusionHigh expression of HSDL2 plays an important role in the progression of PC and might be a potential new biomarker of poor prognosis as well as a therapeutic target in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.